Twenty schizophrenic inpatients with either predominantly positive or
predominantly negative symptoms were treated with the dopamine autoreceptor
agonist roxindole in prospective open clinical trials. There was no
antipsychotic effect in the subgroup with positive symptoms, whereas the
subgroup with negative symptoms, especially those with the residual type of
schizophrenia, showed a moderate but significant 20% reduction in total
scores on the Scale for the Assessment of Negative Symptoms.